Article: Focalin(TM) LA Pivotal Clinical Trial Initiated in Adults With ADD/ADHD.

Celgene Corporation announced today that a pivotal clinical trial of Focalin(TM) LA (dexmethylphenidate hydrochloride extended-release capsules) in adults with attention deficit disorder / attention deficit hyperactivity disorder (ADD/ADHD) has been initiated. Novartis Pharmaceuticals Corporation has marketing rights to Focalin LA in the United States and will conduct the multi-center, controlled pivotal trial to evaluate the safety and efficacy of Focalin LA administered once daily in adult patients with ADD/ADHD.

Attention deficit disorder/attention deficit hyperactivity disorder is a recognized medical disorder characterized by persistent symptoms of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!